References
1. de Medeiros VLS, Silva LFT. Follow-up of skin lesions during the evolution of COVID-19: A case report. Arch Dermatol Res 2021;313 :603–606.
2. Lim SYD, Tey HL. Response to ’Classification of the cutaneous manifestations of COVID-19: a rapid prospective nationwide consensus study in Spain with 375 cases’: vesicular eruption in COVID-19 - to exclude varicella. Br J Dermatol 2020;183 :790–791.
3. Iavarone C, O’hagan DT, Yu D, Delahaye NF, Ulmer JB. Mechanism of action of mRNA-based vaccines. Expert Rev Vaccines 2017;16 :871–881.
4. Toscano G, Palmerini F, Ravaglia S, et al. Guillain-Barré syndrome associated with SARS-CoV-2. N Engl J Med 2020;382 :2574–2576.
5. Moro F, Fania L, Sinagra JLM, Salemme A, Di Zenzo G. Bullous pemphigoid: trigger and predisposing factors.Biomolecules 2020;10 :1432.
6. Schiavo AL, Ruocco E, Brancaccio G, Caccavale S, Ruocco V, Wolf R. Bullous pemphigoid: etiology, pathogenesis, and inducing factors: facts and controversies. Clin Dermatol 2013;31 :391–399.
7. Drago F, Nozza P, Casazza S, Brusati C, Bandelloni R, Rebora A. Human herpesviruses in bullous pemphigoid lesions. Br J Dermatol 2005;152 :375–376.